Pegylated liposomal doxorubicin in ovarian cancer.
The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.
Strother
Robert
R
Department of Medicine.
Matei
Daniela
D
Ann Intern Med. 1984 Dec;101(6):798-9
6497196
Cancer Chemother Pharmacol. 1999;44(4):303-6
10447577
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
16445612
J Clin Oncol. 1995 Jul;13(7):1777-85
7602367
Gynecol Oncol. 2005 Aug;98(2):267-73
15975643
Cancer Res. 1994 Feb 15;54(4):987-92
8313389
Clin Pharmacokinet. 2003;42(5):419-36
12739982
Oncology. 2009;76(1):49-54
19039248
J Clin Oncol. 2009 Mar 20;27(9):1419-25
19224846
Clin Cancer Res. 2000 Jun;6(6):2528-37
10873109
Ann Oncol. 2006 Jan;17(1):93-6
16282248
Anticancer Res. 2008 Mar-Apr;28(2B):1329-34
18505074
Oncology. 2002;62(3):216-22
12065868
Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34
11702367
Eur J Dermatol. 2008 Sep-Oct;18(5):566-70
18693162
Ann Oncol. 2004 Oct;15(10):1566-73
15367419
Ann Oncol. 2005 Feb;16(2):300-6
15668288
Gynecol Oncol. 2007 Dec;107(3):518-25
17910981
BMC Cancer. 2006 Aug 01;6:202
16882344
J Control Release. 1998 Apr 30;53(1-3):275-9
9741935
Eur J Cancer Clin Oncol. 1989 Dec;25(12):1795-803
2632261
Gynecol Oncol. 2007 Aug;106(2):375-80
17512575
Gynecol Oncol. 2001 May;81(2):206-12
11330951
Ann Oncol. 2007 Feb;18(2):263-8
17108151
Gynecol Oncol. 2004 May;93(2):513-6
15099971
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949-53
3413128
J Pharmacol Exp Ther. 1997 Mar;280(3):1319-27
9067319
J Control Release. 2006 Oct 27;115(3):251-8
17045355
Gynecol Oncol. 2006 Feb;100(2):318-23
16239023
Clin Cancer Res. 1999 Nov;5(11):3645-52
10589782
Ann Biol Clin (Paris). 1993;51(9):811-3
8166395
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1212-4
15161947
Ann Oncol. 2003 Sep;14(9):1406-11
12954580
Am J Clin Oncol. 2006 Aug;29(4):399-404
16891870
Lancet. 1981 Aug 1;2(8240):241-6
6114292
Gynecol Oncol. 2008 Jan;108(1):90-4
17949799
Clin Cancer Res. 2004 Jun 1;10(11):3919-26
15173101
Gynecol Oncol. 2004 Oct;95(1):1-8
15385103
Ann Oncol. 2007 Jul;18(7):1159-64
17229768
Biochim Biophys Acta. 1990 Nov 16;1029(2):285-94
2245212
Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
15717738
J Am Acad Dermatol. 2008 Feb;58(2 Suppl):S44-6
18191705
Cancer. 2003 Aug 1;98(3):610-7
12879480
Biochim Biophys Acta. 2004 May 27;1663(1-2):167-77
15157619
Anticancer Res. 2003 Jul-Aug;23(4):3543-8
12926104
Clin Pharmacokinet. 1988 Jul;15(1):15-31
3042244
Gynecol Oncol. 2000 Aug;78(2):143-7
10926793
J Am Acad Dermatol. 2008 May;58(5 Suppl 1):S84-7
18489055
Gynecol Oncol. 2004 Jul;94(1):147-51
15262133
Cancer Res. 1982 Nov;42(11):4734-9
7127308
Lancet. 1987 Sep 12;2(8559):624-5
2887906
Cancer Chemother Pharmacol. 2008 Apr;61(4):695-702
17549475
J Clin Oncol. 2007 Jul 1;25(19):2811-8
17602086
J Clin Oncol. 2001 Jul 15;19(14):3312-22
11454878
Oncologist. 2007 Jan;12(1):72-8
17227902
Ann Oncol. 2006 Jun;17(6):957-61
16600975
Clin Cancer Res. 2005 Aug 15;11(16):5912-9
16115933
Cancer. 2002 Nov 15;95(10):2223-9
12412177
Gynecol Oncol. 2006 Oct;103(1):212-8
16677696
J Pharmacol Sci. 2004 Jul;95(3):381-9
15272215
Gynecol Oncol. 2007 Jul;106(1):164-9
17481704
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Am J Clin Oncol. 2008 Oct;31(5):476-80
18838885
Anticancer Drugs. 2003 Sep;14(8):633-8
14501385
Cancer. 2000 Sep 1;89(5):1037-47
10964334
Br J Cancer. 2003 Oct 6;89(7):1180-4
14520442
Eur J Cancer. 2002 Oct;38(15):1992-7
12376203
Cancer Invest. 2005;23(8):665-70
16377584
Gynecol Oncol. 2005 May;97(2):374-8
15863132
Int J Clin Oncol. 2008 Apr;13(2):156-60
18463961
Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72
10985896
Int J Gynecol Cancer. 2007 May-Jun;17(3):589-94
17300679
Anticancer Res. 2006 Jan-Feb;26(1B):745-50
16739347
Int J Clin Oncol. 2008 Aug;13(4):330-4
18704633
Gynecol Oncol. 2002 Apr;85(1):136-9
11925133
Br J Clin Pharmacol. 2000 Oct;50(4):315-24
11012554
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):223-7
17511800
Ann Intern Med. 1979 Nov;91(5):710-7
496103
Invest New Drugs. 2006 Sep;24(5):413-21
16763786
Gynecol Oncol. 2006 Oct;103(1):72-4
16494932
Cancer Invest. 2004;22(5):663-9
15581046
J Clin Oncol. 2008 Feb 20;26(6):890-6
18281662
Cancer Chemother Pharmacol. 1979;3(2):81-5
389479
Cancer Res. 1982 Apr;42(4):1412-22
7060015
Oncology. 2005;69(6):463-9
16374040